Safer sedation for awake intubation? trial tests drug combo
NCT ID NCT06581731
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial compares two sedation approaches for awake fiberoptic intubation, a procedure where a breathing tube is placed while the patient is conscious. One group receives remifentanil alone, while the other gets a combination of dexmedetomidine and remifentanil. The study measures how well the vocal cords open, coughing, and movement during the procedure, as well as side effects like low oxygen or blood pressure changes. Participants are adults aged 18-65 scheduled for elective cervical spine surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remifentanil, remimazolam, dexmedetomidine
- What this could lead to
- If one sedation method proves safer or more effective, it could become the preferred approach for awake intubation, reducing patient discomfort and complications.
- What could go wrong
- This is a small, early-stage trial with only 64 participants, so results may not apply to all patients. Both sedation methods carry risks like low oxygen or blood pressure changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFICULT OR FAILED INTUBATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing First Hospital
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.